Literature DB >> 14643300

Mechanisms of increased immunogenicity for DNA-based vaccines adsorbed onto cationic microparticles.

Kimberly S Denis-Mize1, Marc Dupuis, Manmohan Singh, Carolyn Woo, Mildred Ugozzoli, Derek T O'Hagan, John J Donnelly, Gary Ott, Donald M McDonald.   

Abstract

Investigation into the mechanism of action of vaccine adjuvants provides opportunities to define basic immune principles underlying the induction of strong immune responses and insights useful for the rational development of subunit vaccines. A novel HIV vaccine composed of plasmid DNA-encoding p55 gag formulated with poly-lactide-co-glycolide microparticles (PLG) and cetyl trimethyl ammonium bromide (CTAB) elicits both serum antibody titers and cytotoxic lymphocyte activity in mice at doses two orders of magnitude lower than those required for comparable response to plasmid DNA in saline. Using this model, we demonstrated the increase in potency requires the DNA to be complexed to the PLG-CTAB microparticles. Furthermore, the PLG-CTAB-DNA formulation increased the persistence of DNA at the injection site, recruited mononuclear phagocytes to the site of injection, and activated a population of antigen presenting cells. Intramuscular immunization with the PLG-CTAB-DNA complex induced antigen expression at both the injection site and the draining lymph node. These findings demonstrate that the PLG-CTAB-DNA formulation exhibits multiple mechanisms of immunopotentiation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14643300     DOI: 10.1016/j.cellimm.2003.09.003

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  13 in total

1.  High loading efficiency and tunable release of plasmid DNA encapsulated in submicron particles fabricated from PLGA conjugated with poly-L-lysine.

Authors:  Jeremy S Blum; W Mark Saltzman
Journal:  J Control Release       Date:  2008-04-16       Impact factor: 9.776

2.  CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine.

Authors:  Hang Xie; Ihsan Gursel; Bruce E Ivins; Manmohan Singh; Derek T O'Hagan; Jeffrey B Ulmer; Dennis M Klinman
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

3.  Polymeric Materials for Gene Delivery and DNA Vaccination.

Authors:  David N Nguyen; Jordan J Green; Juliana M Chan; Robert Longer; Daniel G Anderson
Journal:  Adv Mater       Date:  2008-12-04       Impact factor: 30.849

4.  In vitro and in vivo mRNA delivery using lipid-enveloped pH-responsive polymer nanoparticles.

Authors:  Xingfang Su; Jennifer Fricke; Daniel G Kavanagh; Darrell J Irvine
Journal:  Mol Pharm       Date:  2011-04-01       Impact factor: 4.939

5.  Dose-dependent protection against or exacerbation of disease by a polylactide glycolide microparticle-adsorbed, alphavirus-based measles virus DNA vaccine in rhesus macaques.

Authors:  Chien-Hsiung Pan; Nitya Nair; Robert J Adams; M Christine Zink; Eun-Young Lee; Fernando P Polack; Manmohan Singh; Derek T O'Hagan; Diane E Griffin
Journal:  Clin Vaccine Immunol       Date:  2008-02-20

6.  Use of Vaxfectin adjuvant with DNA vaccine encoding the measles virus hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques against measles virus.

Authors:  Chien-Hsiung Pan; Gretchen S Jimenez; Nitya Nair; Qun Wei; Robert J Adams; Fernando P Polack; Alain Rolland; Adrián Vilalta; Diane E Griffin
Journal:  Clin Vaccine Immunol       Date:  2008-06-04

Review 7.  Current advances in research and clinical applications of PLGA-based nanotechnology.

Authors:  Jian-Ming Lü; Xinwen Wang; Christian Marin-Muller; Hao Wang; Peter H Lin; Qizhi Yao; Changyi Chen
Journal:  Expert Rev Mol Diagn       Date:  2009-05       Impact factor: 5.225

8.  Vaxfectin adjuvant improves antibody responses of juvenile rhesus macaques to a DNA vaccine encoding the measles virus hemagglutinin and fusion proteins.

Authors:  Wen-Hsuan W Lin; Adrian Vilalta; Robert J Adams; Alain Rolland; Sean M Sullivan; Diane E Griffin
Journal:  J Virol       Date:  2013-04-03       Impact factor: 5.103

9.  Liposomal delivery of p-ialB and p-omp25 DNA vaccines improves immunogenicity but fails to provide full protection against B. melitensis challenge.

Authors:  Nicola J Commander; James M Brewer; Brendan W Wren; Stephen A Spencer; Alastair P Macmillan; Judith A Stack
Journal:  Genet Vaccines Ther       Date:  2010-07-16

Review 10.  Current progress in gene delivery technology based on chemical methods and nano-carriers.

Authors:  Lian Jin; Xin Zeng; Ming Liu; Yan Deng; Nongyue He
Journal:  Theranostics       Date:  2014-01-15       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.